UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1720) 1720
humans (1715) 1715
life sciences & biomedicine (1648) 1648
male (898) 898
thiophenes - therapeutic use (784) 784
thiophenes - pharmacokinetics (753) 753
pharmacology & pharmacy (746) 746
animals (725) 725
thiophenes - pharmacology (688) 688
female (677) 677
thiophenes - administration & dosage (617) 617
thiophenes - adverse effects (517) 517
rivaroxaban (482) 482
middle aged (437) 437
adult (394) 394
aged (348) 348
administration, oral (337) 337
dose-response relationship, drug (312) 312
rats (297) 297
treatment outcome (293) 293
cardiovascular system & cardiology (275) 275
prasugrel hydrochloride (273) 273
morpholines - therapeutic use (250) 250
thiophenes - chemistry (231) 231
dabigatran (229) 229
anticoagulants (213) 213
anticoagulants - therapeutic use (210) 210
drug therapy (203) 203
mice (203) 203
analysis (194) 194
morpholines - administration & dosage (193) 193
chemistry (192) 192
ticlopidine - analogs & derivatives (190) 190
pharmacokinetics (183) 183
hematology (182) 182
medicine & public health (182) 182
physical sciences (182) 182
drug interactions (180) 180
duloxetine hydrochloride (178) 178
beta-alanine - analogs & derivatives (175) 175
factor xa inhibitors (173) 173
anticoagulants - administration & dosage (171) 171
morpholines - adverse effects (171) 171
thiophenes - blood (168) 168
anticoagulants - adverse effects (159) 159
double-blind method (157) 157
cardiac & cardiovascular systems (156) 156
pharmacology/toxicology (153) 153
piperazines - therapeutic use (152) 152
peripheral vascular disease (151) 151
thiophene (151) 151
abridged index medicus (143) 143
prasugrel (142) 142
platelet aggregation inhibitors - therapeutic use (140) 140
morpholines - pharmacokinetics (139) 139
benzimidazoles - therapeutic use (137) 137
hemorrhage - chemically induced (137) 137
oncology (135) 135
research (133) 133
internal medicine (132) 132
structure-activity relationship (132) 132
clinical trials as topic (130) 130
rats, sprague-dawley (129) 129
biochemistry & molecular biology (124) 124
neurosciences & neurology (123) 123
pyrazoles - therapeutic use (120) 120
time factors (120) 120
morpholines - pharmacology (119) 119
young adult (118) 118
piperazines - pharmacokinetics (117) 117
pyridones - therapeutic use (115) 115
thiophenes - metabolism (114) 114
anticoagulants - pharmacokinetics (112) 112
general & internal medicine (111) 111
thiophenes - chemical synthesis (111) 111
care and treatment (110) 110
ticlopidine - therapeutic use (110) 110
clopidogrel (109) 109
piperazines - pharmacology (108) 108
aged, 80 and over (106) 106
acute coronary syndrome - drug therapy (105) 105
adolescent (105) 105
randomized controlled trials as topic (104) 104
toxicology (104) 104
drug therapy, combination (103) 103
pharmacology (103) 103
piperazines - adverse effects (102) 102
medicine, general & internal (101) 101
platelet aggregation inhibitors - pharmacokinetics (99) 99
chemistry, medicinal (98) 98
duloxetine (98) 98
area under curve (97) 97
clinical trials (97) 97
risk factors (97) 97
atrial fibrillation (96) 96
beta-alanine - therapeutic use (96) 96
platelet aggregation inhibitors - pharmacology (96) 96
platelet aggregation inhibitors - adverse effects (95) 95
atrial fibrillation - drug therapy (94) 94
drug administration schedule (94) 94
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2159) 2159
German (36) 36
French (13) 13
Japanese (12) 12
Spanish (5) 5
Chinese (4) 4
Portuguese (3) 3
Russian (3) 3
Hungarian (2) 2
Danish (1) 1
Dutch (1) 1
Italian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 11/2014, Volume 75, Issue 1, pp. 183 - 189
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Eligibility criteria... 
Medicine & Public Health | MEK Inhibitor | Afuresertib | Oncology | Cancer Research | Pharmacology/Toxicology | Combination therapy | AKT Inhibitor | Trametinib | MEK inhibitor | AKT inhibitor | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Thiophenes - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Pyridones - administration & dosage | Multiple Myeloma - drug therapy | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Multiple Myeloma - enzymology | Pyrazoles - pharmacokinetics | Multiple Myeloma - blood | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasms - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Pyrimidinones - pharmacokinetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Pyridones - therapeutic use | Pyrimidinones - administration & dosage | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - adverse effects | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Gastrointestinal diseases | Multiple myeloma | Melanoma | Medicine, Experimental | Aspartate | Nausea | Tumors | Index Medicus
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 05/2009, Volume 119, Issue 19, pp. 2553 - 2560
Background-Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with... 
Drugs | Cardiovascular diseases | Genetics | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Myocardial Infarction - mortality | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Biotransformation - genetics | Cytochrome P-450 Enzyme System - metabolism | Male | Young Adult | Receptors, Purinergic P2Y12 | Cardiovascular Diseases - mortality | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Microsomes, Liver - enzymology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Piperazines - pharmacokinetics | Stroke - mortality | Platelet Aggregation Inhibitors - therapeutic use | Stroke - prevention & control | Purinergic P2 Receptor Antagonists | Thiophenes - pharmacology | Genotype | Treatment Outcome | Piperazines - therapeutic use | Piperazines - pharmacology | Aryl Hydrocarbon Hydroxylases - metabolism | Polymorphism, Genetic | Thiophenes - pharmacokinetics | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Cytochrome P-450 Enzyme System - genetics | Aged | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Prodrugs - pharmacology | Care and treatment | Demographic aspects | Patient outcomes | Cytochrome P-450 | Genetic aspects | Research | Genetic polymorphisms | Heart attack | Index Medicus | Abridged Index Medicus
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
...) and breast cancer resistance protein (Bcrp) (ABCG2). Methods The pharmacokinetic effects of substrates or inhibitors of CYP3A4, P‐gp and Bcrp (ABCG2... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article